Stockreport

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 [Yahoo! Finance]

Neuropace, Inc.  (NPCE) 
PDF — American Academy of Neurology (AAN) presentation featured 12- and 18-month NAUTILUS data, the first randomized controlled trial of neuromodulation in drug-resistant i [Read more]